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Abstract
The dupA gene of Helicobacter pylori was suggested to be a risk factor for duodenal ulcer but protective against gastric cancer. The pres-
ent study aimed to re-examine the role of dupA in H. pylori-infected Japanese patients. We found that dupA status was not associated
with any gastroduodenal disease, histological score of chronic gastritis or with the extent of interleukin-8 production from gastric cell
lines. These results indicate that dupA is unlikely to be a virulence factor of H. pylori in the Japanese population.
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Introduction
Helicobacter pylori is a spiral bacterium that chronically infects
the human stomach and plays a causative role in gastritis,
duodenal ulcer (DU), gastric ulcer (GU), gastric cancer (GC)
and mucosa-associated lymphoid tissue lymphoma [1,2].
However, only a minority of H. pylori-infected patients
develop severe disease, suggesting that clinical outcomes are
determined by the interaction of bacterial virulence, host
genetic susceptibility and environmental factors [3].
Several H. pylori virulence factors associated with peptic
ulcer and GC have been reported, including vacA, cagA, babA
and oipA [2,4–7]. Most recently, Lu et al. [8] described a
novel virulence factor, duodenal ulcer promoting gene
(dupA), which consists of two open reading frames jhp0917
and jhp0918 located in the plasticity region of the H. pylori
genome. Interestingly, dupA is homologous to virB4, a gene
encoding a component protein of the type IV secretion sys-
tem (TFSS) in Agrobacterium tumefaciens. Lu et al. [8]
reported that infections with dupA-positive strains increased
the risk for DU but were protective against gastric atrophy,
intestinal metaplasia and GC in the Japanese, Korean and
Columbian subjects. Intriguingly, dupA is the ﬁrst genetic fac-
tor of H. pylori to be associated with differential susceptibility
to DU and GC, and thus it could be considered as a disease-
speciﬁc virulence marker. The pathogenic mechanism of dupA
appears to involve the induction of high interleukin (IL)-8
production in the antrum, leading to antrum-predominant
gastritis, a well-recognized characteristic of DU [8].
However, the role of dupA was questioned subsequently
when a number of studies were unable to reproduce the
observations of Lu et al. [8] in other populations [9–12].
Because the role of dupA as a virulence marker is still con-
troversial, in the present study, we attempted to re-examine
the relationship between dupA and gastroduodenal diseases
in a Japanese population.
Materials and Methods
Patients
A total of 244 Japanese patients (114 females, 130 males)
aged 21–91 years (mean 57.5 years) were recruited
(Table 1).
Ethical approval and written informed consent were
obtained from all participants before the study. Four biopsy
samples (two from the antrum, two from the corpus) were
taken endoscopically from each patient and used for H. pylori
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culture and histopathologic examination. GU and DU were
determined by endoscopic observation, and non-cardia GC
and chronic gastritis were diagnosed histologically, as
described previously [13–15].
Histology
Biopsy specimens from the antrum and corpus were exam-
ined by an experienced pathologist (M.K.) who was unaware
of the characteristics of the infecting H. pylori strain. For each
biopsy specimen, the grade of neutrophil inﬁltration, mono-
nuclear cell inﬁltration, atrophy and intestinal metaplasia
were scored on the basis of the updated Sydney System (0,
none; 1, mild; 2, moderate; and 3, severe) [15].
H. pylori culture and genomic DNA extraction
For H. pylori isolation, biopsy specimens were homogenized
and inoculated onto Mueller Hinton II Agar medium (Becton
Dickinson, Frankin Lakes, NJ, USA) supplemented with 7%
horse blood. The culture plates were incubated for 4 days at
37C under microaerophilic conditions (10% O2, 5% CO2
and 85% N2). Samples from multiple colonies were pooled
and stored at )80 C in Brucella Broth (Difco, Frankin
Lakes, NJ, USA) containing 10% dimethylsulphoxide and 10%
horse serum.
For DNA extraction, H. pylori was subcultured from the
stock. Multiple colonies on the agar plates were harvested
and genomic DNA was extracted according to a standard
phenol–chloroform method.
Detection of jhp0917, jhp0918, cagA and cagE
To detect the presence of jhp0917 and jhp0918, we used a
PCR method with the two sets of primers designed by Lu
et al. [8] (Table 2). The ampliﬁed DNA fragments were sepa-
rated electrophoretically on 1% agarose gel, stained with
ethidium bromide and visualized under ultraviolet light.
To avoid false-negative results on PCR as a result of varia-
tions in the primer annealing sites, a dot blot was performed
in all cases. For each single dot, 100 ng of sample DNA was
mixed with 100 lL of denaturing buffer (0.8 M NaOH, 1.5 M
NaCl) and spotted onto a Hybond N+ membrane
(Amersham Biosciences, Little Chalfont, UK) via the 96-well
Bio-Dot apparatus (Bio-Rad, Ivry-sur-Seine, France). DNA
from the reference strain J99 (GenBank accession number
AE001439) and human DNA were used as positive and nega-
tive controls, respectively. Human DNA was extracted from
peripheral blood cells.
Parts of jhp0917 and jhp0918 were ampliﬁed by PCR using
the corresponding primer sets (Table 2). The ampliﬁed frag-
ments were puriﬁed with Illustra GFX PCR DNA and Gel
Band Puriﬁcation kit (Amersham Biosciences) and used as
probes. With the use of ECL Direct Nucleic Acid Labeling
and Detection Systems (Amersham Biosciences), the probes
were labelled with horseradish peroxidase, hybridized to the
membrane at 42C overnight and ﬁnally exposed to Hyper-
ﬁlm ECL.
cagA and cagE were detected by a PCR method using the
primer sets described previously (Table 2) [16].
Nucleotide sequencing
A DNA fragment covering the intergenic region between
jhp0917 and jhp0918 was ampliﬁed with the primer set dupA
(Table 2). The ampliﬁed fragments were sequenced with a
Big Dye Terminator v3.1 Cycle Sequencing kit on a ABI
Prism 310 Genetic Analyzer (Applied Biosystems, Foster
City, CA, USA).
The signal sequence of H. pylori oipA was also sequenced
as described previously (Table 2) [7].
RNA extraction and RT-PCR
H. pylori RNA was isolated with ISOGEN (Nippongene, Toy-
ama, Japan) and then treated with DNase I (Takara Biotech-
TABLE 1. Characteristics of the study population
Number of patients 244
Age, mean ± SD (years) 57.5 ± 14.1
Female/male 114/130
Diseases
Chronic gastritis 84
Duodenal ulcer 63
Gastric ulcer 61
Non-cardia gastric cancer 36
Diffuse type 4
Intestinal type 30
Mixed type 2
TABLE 2. List of primers used in the present study
Gene Primer Primer sequence (5¢- to 3¢)
PCR
product
size (bp)
jhp0917a jhp0917-F TGGTTTCTACTGACAGAGCGC 307
jhp0917-R AACACGCTGACAGGACAATCTCCC
jhp0918a jhp0918-F CCTATATCGCTAACGCGCGCTC 276
jhp0918-R AAGCTGAAGCGTTTGTAACG
dupA dupA-F TAAGCGTGATCAATATGGAT 350
dupA-R TGGAACGCCGCATTCTATTA
cagAb CagA-F1 AACAGGACAAGTAGCTAGCC 701
CagA-R1 TATTAATGCGTGTGTGGCTG
CagA-F2 GATAACAGGCAAGCTTTTGA 349
CagA-R2 CTGCAAAAGATTGTTTGGCAGA
cagEb CagE-F GCGATTGTTATTGTGCTTGTAG 329
CagE-R GAAGTGGTTAAAAAATCAATGCCCC
oipAc OipA-F CCATGAAAAAAGCTCTCTTAC 516
OipA-R GCCCTTTTACCCTTCGTTCAAC
16S rRNAd 16S rRNA-F TGGCAATCAGCGTCAGGTAATG 520
16S rRNA-R GCTAAGAGATCAGCCTATGTCC
aLu et al. [8].
bIkenoue et al. [16].
cYamaoka et al. [7].
dEngstrand et al. [17].
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nology, Shiga, Japan) to remove DNA contamination. The
absence of DNA contamination was veriﬁed by PCR with a
16S rRNA primer set [17] (Table 2) using RNA as the
template.
For RT-PCR, 500 ng of total RNA was reverse tran-
scribed into cDNA with the Transcriptor First Strand cDNA
Synthesis kit (Roche, Mannheim, Germany). The synthesized
cDNA was then subject to PCR ampliﬁcation with the dupA
primer set and 16S rRNA as a positive control.
Analysis of H. pylori-induced IL-8 production in gastric cell
lines
The experiments were performed independently on two
occasions, each time in duplicate, as described previously
[8,18]. Brieﬂy, AGS and MKN45 cells were seeded into
24-well plates and grown overnight at 37C in RPMI 1640
(Sigma-Aldrich, Ayrshire, UK) medium supplemented with
10% foetal bovine serum.
Randomly selected stock H. pylori strains were cultured
on the agar, harvested and washed twice with phosphate-
buffered saline before being added to the culture wells
(bacterium-to-cell ratio, 100:1). The inoculated plates were
incubated at 37C in 5% CO2 and 95% air for 6 h. The
concentration of IL-8 in the cell culture supernatant was
measured with a Quantikine Human CXCL8/IL-8 ELISA kit
(R&D Systems, Minneapolis, MN, USA).
Results
Prevalence of jhp0917, jhp0918, cagA and cage
Among the 244 H. pylori strains, 68 and 78 were positive for
jhp0917, and 65 and 72 were positive for jhp0918 by PCR
and dot blot, respectively. PCR and dot blot showed incon-
sistent results (negative PCR but positive dot blot) for
jhp0917 and jhp0918 in ten and seven cases, respectively.
Positive results for PCR but negative for dot blot were not
observed. Overall, the agreement between PCR and dot blot
results was 95.9% (234/244) for jhp0917 and 97.1% (237/
244) for jhp0918.
On the basis of the combined results of PCR and dot blot,
72 strains (29.5%) were judged to have both jhp0917 and
jhp0918, whereas 166 (68.0%) possessed neither. The
remaining six strains (2.5%) contained only jhp0917. These
results indicate that jhp0917 and jhp0918 are strongly linked
(p <0.01). cagA and cagE were positive in 98.8% (241/244)
and 98.4% (240/244) of the examined H. pylori strains,
respectively.
dupA status in H. pylori strains from Japan
In strain J99, jhp0917 and jhp0918 are separate genes.
jhp0917 is homologous to the 5¢ end of virB4 but lacks the
3¢ end, whereas jhp0918 is homologous to the 3¢ end of
virB4 but lacks the 5¢ end. However, in many H. pylori strains
possessing both jhp0917 and jhp0918, there is a 1-bp inser-
tion (C or T) after position 1385, resulting in a frameshift
leading to one continuous gene, named dupA, homologous to
the complete virB4 [8]. Therefore, the presence of jhp0917,
jhp0918 and the 1-bp insertion after position 1385 are all
required for the formation of dupA.
To investigate the status of dupA in the H. pylori strains
used in the present study, we analysed the sequence around
position 1385 in the 72 strains that had both jhp0917 and
jhp0918. We found that all of them contained the 1-bp inser-
tion referred to above. Therefore, we conclude that these
72 strains are all dupA-positive, accounting for 29.5% of the
TABLE 3. dupA prevalence in different regions
Region/ethnicity Reference
dupA prevalence (%) by diagnosis
(dupA-positive strains/analysed strains)
Overall CG DU GU GC
Japan [8] 21.3 (34/160) 14.0 (7/50) 36.7 (11/30) 26.0 (13/50) 10 (3/30)
Korea [8] 19.4 (34/175) 6.7 (2/30) 36.9 (24/65) 16.7 (5/30) 6.0 (3/50)
Colombia [8] 33.3 (55/165) 37.5 (15/40) 48.9 (22/45) 40.0 (12/30) 12.0 (6/50)
Indiaa [21] 31.3 (52/166) 22.9 (16/70) 37.5 (36/96) – –
South Africa [9] 84.8 (39/46) 73.3 (11/15) 92.3 (12/13) – 88.9 (16/18)
Belgium [9] 43.7 (59/135) 38.2 (29/76) 50.0 (20/40) – 52.6 (10/19)
USA [9] 43.5 (20/46) 45.0 (9/20) 42.9 (9/21) 66.7 (2/3) –
Iran [10] 49.7 (78/157) 50.0 (34/68) 50.0 (15/30) 39.1 (9/23) 55.6 (20/36)
Brazil [11] 93.9 (445/474) 96.2 (230/239) 92.3 (144/156) – 89.9 (71/79)
Australiaa [12] 37.8 (17/45) 37.8 (17/45) – – –
Swedena [12] 63.5 (33/52) 65.0 (13/20) 63.6 (7/11) – 61.9 (13/21)
Chinese Singaporeans
and Malaysiansa
[12] 41.1 (37/90) 28.9 (15/52) 62.5 (10/16) – 54.5 (12/22)
China [22] 35.3 (127/360) 38.3 (51/133) 45.5 (46/101) 23.4 (11/47) 24.1 (19/79)
Japan This study 28.8 (67/233) 29.5 (23/78) 27.4 (17/62) 28.8 (17/59) 29.4 (10/34)
CG, chronic gastritis; DU, duodenal ulcer, GU, gastric ulcer; GC, gastric cancer.
aFunctional dyspepsia patients with H. pylori infection are considered as CG.
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total strains analysed. Table 3 shows a comparison of the
prevalence of dupA in H. pylori isolates in different disease
states observed in the present study with those reported in
previous studies in a range of populations.
Using BLAST, we collected a total of 89 sequences covering
the intergenic region between jhp0917 and jhp0918 deposited
in GenBank. We found that 95.5% (85/89) of them had the
1-bp insertion after position 1385, whereas 4.5% (4/89) did
not. These results, when taken together with those obtained
in the present study, indicate that most, but not all, strains
possessing both jhp0917 and jhp0918 are dupA-positive.
dupA expression
Previous studies have shown that several genes in the plastic-
ity region are not expressed and can be regarded as pseud-
ogenes [19]. Because dupA is also located in the plasticity
region, we aimed to investigate whether it is a true gene.
RT-PCR of ten randomly selected dupA-positive strains con-
ﬁrmed that dupA was always expressed under the conditions
tested, and thus is a true gene.
Association between dupA and clinical outcomes
To investigate the association between dupA and clinical out-
comes, ﬁve H. pylori strains without cagE and/or cagA and six
strains that had only jhp0917 were excluded from the analy-
sis. Therefore, the analysed population consisted of 233
patients (109 female, 124 male) divided into four disease
groups: chronic gastritis (n = 78), DU (n = 62), GU (n = 59)
and non-cardia GC (n = 34; diffuse type, four cases; intestinal
type, 28 cases; mixed type, two cases). Among these 233
patients, 67 (28.8%) and 166 (71.2%) were infected with
dupA-positive and dupA-negative strains, respectively
(Table 4).
dupA-positive strains were distributed almost equally
among the four disease groups (DU, 27.4%; gastritis, 29.5%;
GU, 28.8%; GC 29.4%) and thus there was no association
between dupA status and clinical outcomes (p >0.05). In the
chronic gastritis group, the histological scores of patients
infected with dupA-positive and -negative strains were not
signiﬁcantly different (1.00 ± 0.90 vs. 1.29 ± 0.66,
2.30 ± 0.47 vs. 2.49 ± 0.57, 1.39 ± 0.66 vs. 1.33 ± 0.80 and
0.35 ± 0.78 vs. 0.4 ± 0.81, and 1.39 ± 0.66 vs. 1.18 ± 0.80,
2.48 ± 0.80 vs. 2.18 ± 0.75, 0.87 ± 1.18 vs. 0.49 ± 0.77 and
0.09 ± 0.29 vs. 0.09 ± 0.40 for neutrophil inﬁltration, mono-
nuclear cell inﬁltration, atrophy and intestinal metaplasia in
the antrum and corpus, respectively) (p >0.05), (Fig. 1a, b).
The prevalence of dupA did not differ signiﬁcantly in patients
with and without atrophy (21/69 vs. 2/9, p >0.05) and in
those with and without intestinal metaplasia (6/21 vs. 17/57,
p >0.05).
Association between IL-8 secretion from gastric cell lines
and dupA status
We compared the ability of dupA-positive and dupA-negative
strains to induce IL-8 secretion from gastric cell lines. Eight
TABLE 4. dupA prevalence in different Helicobacter pylori-
associated diseases
CG
(n = 78)
DU
(n = 62)
GU
(n = 59)
GC
(n = 34)
Total
(n = 233) p value
dupA
positive
23 (29.5%) 17 (27.4%) 17 (28.8%) 10 (29.4%) 67 (28.8%) >0.05
dupA
negative
55 (70.5%) 45 (72.6%) 42 (71.2%) 24 (70.6%) 166 (71.2%) >0.05
CG, chronic gastritis; DU, duodenal ulcer, GU, gastric ulcer; GC, gastric cancer.
(a)
(b)
(c)
FIG. 1. dupA status is not associated with histological scores of
chronic gastritis in either the antrum (a) or the corpus (b). dupA-
positive and -negative strains do not signiﬁcantly differ in their ability
to induce interleukin-8 production from AGS and MKN45 gastric
cell lines (c).
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dupA-positive strains, which had been used for RT-PCR pre-
viously, and ten dupA-negative strains with both cagA and
cagE, were randomly selected and used for the infection
experiments. Because the H. pylori oipA gene also affects IL-8
secretion [20], we sequenced the signal sequence of this
gene in the 18 strains and conﬁrmed that all had oipA in ‘on’
status. We found that the amounts of IL-8 secreted by gas-
tric cell lines (AGS and MKN45) infected with dupA-positive
and dupA-negative strains were not signiﬁcantly different
(670 ± 419 vs. 707 ± 359 pg/mL for AGS, and 1093 ± 687
vs. 1220 ± 420 pg/ml for MKN45) (p >0.05) (Fig. 1c).
Discussion
Originally, Lu et al. [8] reported that the prevalence of dupA
was signiﬁcantly higher in DU (36.7%) than in gastritis (14%),
GU (26%) or GC (10%) in the Japanese population (Table 3),
and proposed that dupA was associated with an increased
risk for DU but was protective against GC [8].
Table 3 reports these ﬁgures from Ref. 7 (not Lu et al.);
please correct as appropriate.
This is in contrast to our results showing that dupA-posi-
tive strains are distributed almost equally among those four
groups of diseases, with no link between dupA status and
type of gastroduodenal disease. Moreover, in contrast to the
results obtained by Lu et al. [8], our data also indicate that
dupA-positive status is not protective against atrophy and
intestinal metaplasia. At present, it is difﬁcult to explain the
differences between the results obtained in the present
study and those of Lu et al. [8] because both studies were
conducted on Japanese patients. However, the discrepancy
might be a result of geographical variation in the prevalence
of dupA because our samples and those of Lu et al. [8] were
obtained from different regions of Japan (Oita and Kyoto,
respectively). Alternatively, the discrepancy might result
from differences in the proportion of gastric cancer subtypes
(diffuse vs. intestinal) and/or the percentage of chronic gas-
tritis patients with atrophy and/or intestinal metaplasia in the
two study populations.
From 2007 to early 2009, six studies have examined the
relationship between dupA status and clinical outcomes but
all failed to reproduce fully the results of Lu et al. Among
them, two studies from India and China supported the role
of dupA in DU, although its association with GC was not
investigated in one [21] and not established in another [22].
Please match the text to each speciﬁc reference citation..
Adding to the controversy, two other studies identiﬁed dupA
as a risk factor, and not as a protective factor, for GC
[9,12]. The remaining two studies, from Brazil and Iran,
showed no association between dupA status and gastroduo-
denal diseases [10,11].
Currently, consensus is likely to be reached on the forma-
tion of the dupA gene from jhp0917 and jhp0918 by a frame-
shift insertion. Furthermore, Gomez et al. [11] have
reported that 14/86 (16.3%) of dupA sequences from Brazil
contained an adenine frameshift insertion after position 1426,
creating a premature stop codon that in turn may have
considerable effects on protein expression or function. This
ﬁnding raises questions about the presence of other similar
frameshift mutations elsewhere in the dupA sequence that
cannot be detected by a simple PCR method. Therefore, fur-
ther studies using immunoblotting with anti-DupA antibody
are required to elucidate the true relationship between dupA
and clinical outcomes.
Using both dupA knockout and clinical strains, Lu et al. [8]
reported that dupA plays a role in induction of IL-8 expres-
sion. By contrast, and consistent with the study by Schmidt
et al. [12], the results obtained in the present study indicate
that clinical H. pylori isolates with or without dupA did not
differ signiﬁcantly in their ability to induce IL-8 secretion
from gastric cell lines. dupA has been reported to be homol-
ogous with virB4, comprising a gene encoding one compo-
nent protein of the TFSS. However, it should be noted that
the TFSS typically consists of 11 virB proteins (virB1–virB11)
and one coupling protein (virD4) [23,24], but other virB and
virD4 genes linked with dupA have not yet been discovered
in the H. pylori genome. Therefore, it is still unclear whether
the dupA gene, together with others, encodes an indepen-
dent TFSS in addition to cagPAI and has a role in the
induction of IL-8, or is just a virB4 homologue by chance.
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